Blinatumomab is a recombinant murine monoclonal bispecific antibody that targets both CD19 antigen expressed by most B-cells and the CD3 antigen present on T cells leading to their engagement, activation of T cells and subsequent lysis of leukemia cells (47). This evidence concerns the gene CD19 and leukemia.